Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Exelixis
Genmab
Myeloid Therapeutics
Genentech, Inc.
Deciphera Pharmaceuticals, LLC
Avacta Life Sciences Ltd
IDEAYA Biosciences
Memorial Sloan Kettering Cancer Center
Innate Pharma
Pfizer
LG Chem
Nurix Therapeutics, Inc.
Jonsson Comprehensive Cancer Center
Monopar Therapeutics
Monopar Therapeutics
Zumutor Biologics Inc.